AU2012306826B2 - Endostatin mutants with mutations at ATP binding sites - Google Patents

Endostatin mutants with mutations at ATP binding sites Download PDF

Info

Publication number
AU2012306826B2
AU2012306826B2 AU2012306826A AU2012306826A AU2012306826B2 AU 2012306826 B2 AU2012306826 B2 AU 2012306826B2 AU 2012306826 A AU2012306826 A AU 2012306826A AU 2012306826 A AU2012306826 A AU 2012306826A AU 2012306826 B2 AU2012306826 B2 AU 2012306826B2
Authority
AU
Australia
Prior art keywords
leu
ser
ala
arg
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012306826A
Other languages
English (en)
Other versions
AU2012306826A1 (en
Inventor
Guodong Chang
Yang Chen
Yan Fu
Peng Liu
Xinan Lu
Yongzhang Luo
Daifu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of AU2012306826A1 publication Critical patent/AU2012306826A1/en
Application granted granted Critical
Publication of AU2012306826B2 publication Critical patent/AU2012306826B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2012306826A 2011-09-09 2012-09-10 Endostatin mutants with mutations at ATP binding sites Active AU2012306826B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110280441 2011-09-09
CN201110280441.8 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (2)

Publication Number Publication Date
AU2012306826A1 AU2012306826A1 (en) 2014-04-03
AU2012306826B2 true AU2012306826B2 (en) 2018-01-04

Family

ID=47831548

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012306826A Active AU2012306826B2 (en) 2011-09-09 2012-09-10 Endostatin mutants with mutations at ATP binding sites

Country Status (9)

Country Link
US (1) US10647968B2 (enExample)
EP (1) EP2754718B1 (enExample)
JP (1) JP6336389B2 (enExample)
CN (2) CN117987505A (enExample)
AU (1) AU2012306826B2 (enExample)
CA (1) CA2848118C (enExample)
IL (1) IL231419A0 (enExample)
RU (1) RU2014113924A (enExample)
WO (1) WO2013034116A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CA3003760A1 (en) * 2014-11-03 2016-05-12 Tsinghua University Drug for inhibiting adipose cell differentiation and insulin resistance
WO2016127948A1 (zh) * 2015-02-13 2016-08-18 清华大学 一种重组蛋白质药物的分子设计
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
WO2018086603A1 (zh) * 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
CA3103035A1 (en) * 2017-07-30 2019-02-07 Tsinghua University Medication for inhibiting dna-pkcs
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
US20100285103A1 (en) * 2006-01-20 2010-11-11 Yongzhang Luo Medicament for treatment of tumors and the use thereof
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
US20100305303A1 (en) * 2007-06-22 2010-12-02 Hanmei Xu Inhibiting agent for inhibition of angiogenesis, a method for preparing the agent, a method for modifying the agent and its use for manufacturing a medicament for treating tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1322246A (zh) * 1997-12-08 2001-11-14 贝斯以色列护理医疗中心 静息蛋白及其使用方法
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN1237072C (zh) * 2000-05-22 2006-01-18 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
WO2009145489A2 (ko) * 2008-04-04 2009-12-03 주식회사 프로셀제약 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
US20100285103A1 (en) * 2006-01-20 2010-11-11 Yongzhang Luo Medicament for treatment of tumors and the use thereof
US20100305303A1 (en) * 2007-06-22 2010-12-02 Hanmei Xu Inhibiting agent for inhibition of angiogenesis, a method for preparing the agent, a method for modifying the agent and its use for manufacturing a medicament for treating tumor
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用

Also Published As

Publication number Publication date
EP2754718A1 (en) 2014-07-16
US10647968B2 (en) 2020-05-12
AU2012306826A1 (en) 2014-04-03
RU2014113924A (ru) 2015-10-20
CN108291248A (zh) 2018-07-17
US20150197733A9 (en) 2015-07-16
EP2754718B1 (en) 2017-12-13
WO2013034116A1 (zh) 2013-03-14
CA2848118C (en) 2023-09-05
CN108291248B (zh) 2024-03-08
HK1251864A1 (zh) 2019-04-26
JP6336389B2 (ja) 2018-06-06
US20140308263A1 (en) 2014-10-16
CA2848118A1 (en) 2013-03-14
IL231419A0 (en) 2014-04-30
JP2014531897A (ja) 2014-12-04
CN117987505A (zh) 2024-05-07
EP2754718A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
AU2012306826B2 (en) Endostatin mutants with mutations at ATP binding sites
KR100950520B1 (ko) 단백질 포스파타제 2ａ에 결합하는 합성 또는 천연단백질, 이의 동정 방법 및 용도
TR201906295T4 (tr) IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
CN115348884B (zh) 用于治疗戈谢病的β-葡糖脑苷脂酶变体
CN101875693B (zh) 具备抗血管生成活性的白蛋白变异体及其制备方法
CN115850387A (zh) 超高亲和力的靶向pd-l1的小蛋白及药物组合物
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CN114588273B (zh) 一种抑制肿瘤免疫逃逸多肽的应用
CN103319605B (zh) 一种肝靶向肽与血管生成抑制因子融合蛋白及其制备方法与应用
EP2004680B1 (en) N-terminal vdac variants and uses thereof
CN115433268A (zh) 一种肿瘤抑制肽
CN112423779B (zh) 用于治疗色素性视网膜炎的肽
HK1194771A (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
HK1194771B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
WO2020182768A1 (en) Methods for bioactive lectin production with improved yield
CN107082799B (zh) 一种抗肿瘤多肽husp-48及其应用
CN115521360A (zh) 特异性结合Sestrin2蛋白的多肽及其在消化道癌治疗中的应用
HK1251864B (zh) 对atp结合位点进行突变的血管内皮抑制素突变体
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
WO2022218997A1 (en) Novel universal vaccine presenting system
CN119591675A (zh) 多肽、核酸、表达载体、药物组合物及其用途
Akella et al. Abboud, HE see H. Kiyomoto (353) 217 Abdelatty, F. see P. Uetz (339) 302 Abdulkarim, F., L. Liljas and D. Hughes, Mutations to kirromycin resistance occur in the interface of domains I and III of EF-Tu. GTP (352) 118
Yonally The mitochondrial F1F0 ATP synthase: Multienzyme associations and membrane locations
WO2013028527A1 (en) Compositions and methods for treating cancer
NZ751506B2 (en) Immunotherapy for polyomaviruses

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ENDOSTATIN MUTANTS WITH MUTATIONS AT ATP BINDING SITES

FGA Letters patent sealed or granted (standard patent)